A Global Partnership Advancing Biopharmaceutical Development: Summary And Future Perspectives

Upon reading the preceding book chapters, it is clear that comprehensive analysis of monoclonal antibody therapeutics is no easy task. These molecules embody various complex attributes, the characterization of which is a long and arduous process, yet monoclonal antibody therapeutics have taken residence as perhaps one of the most influential therapeutic classes of our time. The intent of this book series was to provide a comprehensive overview of monoclonal antibody therapeutics, using the NISTmAb as a vehicle for highlighting the characterization stages of product development. The preceding chapters represent a collaborative effort among biopharmaceutical professionals rising to this challenge. Contributors utilized the NISTmAb throughout, demonstrated the potential utility of class-specific reference materials as a means to facilitate open innovation, and identified a number of emerging research areas for future development. Conclusion of the series is therefore met with eager anticipation of continued biopharmaceutical advancement through industry-focused partnerships.